EGFR and neoplasm: Serial evaluation of mutant plasma DNA could provide a noninvasive assessment of therapy response and tumor progression, including the detection of resistance mutations or an increase of EGFR sensitizing mutations associated with clinical progression12, 13, 14, 15, 16, 17.